Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 281-285

  Zhang, Daqing ^a   Che, Dongfang ^a   Zhao, Shuiping ^b   Sun, Yingxian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adipocytes; C reactive protein; Cholesterol; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CULTURE; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; IMMUNOASSAY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RABBIT; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; SUPERNATANT;

ADIPOCYTES; ANIMALS; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; MALE; NEPHELOMETRY AND TURBIDIMETRY; PPAR GAMMA; PYRROLES; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 34548749918     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180950248     Document Type: Article

References (39)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-118.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
3. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
4. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
5. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-2150.
6. . Moshage HJ, Roelofs HM, van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun. 1988;155:112-117.
7. Calabro P, Chang DW,Willerson JT, et al. Release of C-reactive protein in response to inflammatory cyokines by human adipocytes: Linking obesity to vascular inflammation. J Am Coll Cardiol. 2005;46:1112-1113.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227-239.
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
10. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006;26:85S-97S.
11. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on serum concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
12. Marz W, Winkler K, Nauck M, et al. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol. 2003;92:305-308.
13. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science. 1999;284:757-760.
14. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453-459.
15. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
16. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibiton by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
17. Rodbell M. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1963;239:375-380.
18. Zhang HH, Kumar S, Barnett AH, et al. Ceiling culture of mature human adipocytes: use in studies of adipocyte functions. J Endocrinol. 2000;164:119-128.
19. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia -induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2660-2665.
20. Musiap J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247-53.
21. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-987.
22. Han SN, Leka LS, Lichtenstein AH, et al. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002;43:445-452.
23. Rahman SM, Van Dam AM, Schultzberg M, et al. High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice. J Neuroimmunol. 2005;169:59-67.
24. Wu DM, Chu NF, Shen MH, et al. Obesity, serum high sensitivity C-reactive protein levels and insulin resistance status among school children in Taiwan. Clin Biochem. 2006;39:810-815.
25. Dvorakova-Lorenzova A, Suchanek P, Havel PJ, et al. The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism. 2006:55:359-365.
26. Rasouli M, Kiasari AM, Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clin Biochem. 2006:39:971-977.
27. Sun HJ, T Koike, Ichikawa T, et al. C-reactive protein in Atherosclerotic Lesions. Am J Pathol. 2005:167:1139-1148.
28. Krause BR, Hartman AD. Adipose tissue and cholesterol metabolism. J Lipid Res. 1984;25:97-110.
29. Fajas L, Schoonjas K, Gelman L, et al. Regulation of peroxisome proliferator-activated receptor g expression by adipocyte differentiation and determination factor 1/sterolregulatory element binding protein 1: Implications for adipocyte differentiation and metabolism. Mol Cell Biol. 1999;19:5495-5503.
30. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
31. Zhao SP, Zhang DQ. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta. 2003;336:103-108.
32. Macin SM, Perna ER, Farias EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo- controlled study. Am Heart J. 2005;149:451-457.
33. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447-1452.
34. Rowe IF, Soutar AK, Trayner IM, et al. Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. J Exp Med. 1984;159:604-616.
35. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217.
36. Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human messangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-540.
37. Niemann-Jonsson A, Dimayuga P, Jovinge S, et al. Accumulation of IDL in rat arteries is associated with activation of tumor necrosis factora expression. Arterioscler Thromb Vasc Biol. 2000;20:2205-2221.
38. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51:58-62.
39. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARgamma and NF- kappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147-154.